Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Slides:

Advertisements

Similar presentations

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Weng TC, et al. J Clin Pharm Ther 2010;35:

APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Clinical Outcomes with Newer Antihyperglycemic Agents

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.

Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

The ALERT Trial.

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

LDL cholesterol in CKD—to treat or not to treat?

Volume 82, Issue 6, Pages (September 2012)

The IDEAL Study Reference

Copyright © 2012 American Medical Association. All rights reserved.

What is the likely mechanism by which HDL-C reduces coronary heart disease?

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

TNT Study: Baseline Characteristics of the Patients

Jun M, et al. Lancet 2010 Epub May 10

Fellström BC, et al. N Engl J Med 2009;360:1455-7

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

I. Introduction American Journal of Kidney Diseases

David J.A. Jenkins et al. JACC 2018;71:

Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]

Classification of statins/dosages according to the attainable

Potential mechanisms whereby statins may reduce the risk of stroke

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

LDL cholesterol in CKD—to treat or not to treat?

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Flow of Patients Through the Trial

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Volume 76, Issue 11, Pages (December 2009)

Flow Diagram of the Trial Selection Process

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Volume 82, Issue 6, Pages (September 2012)

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Delahoy PJ, et al. Clin Ther 2009;31:236-44

Characteristics of included studies

Brugts JJ, et al. BMJ 2009;338:b2376.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Change in markers of glycometabolism and cardiovascular risk profile.

Adjusted relative risk Adjusted odds ratio

The selection process for randomised controlled trials (RCTs) and cohort studies on omega 3 fatty acid and health outcomes Lee Hooper, BMJ 2006 Mar 24;

Lipids, the Heart, and the Kidney

Characteristics of 3415 patients admitted to hospital with

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

LDL-c reductions below 1

James H O'Keefe, Jr et al. JACC 2004;43:

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Characteristics of populations, interventions, and outcomes in included trials – Part I Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Characteristics of populations, interventions, and outcomes in included trials – Part II

Effects of statins on lipid concentrations and renal function in patients with chronic kidney disease Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Univariatemeta-regression analysis of potential sources of heterogeneity on effect of statins versus placebo on total cholesterol and lowdensity lipoprotein (LDL) cholesterol at end of study Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Effect of statins compared with placebo or no treatment on all cause mortality in pre-dialysis, dialysis, and transplant patients Almost all studies reported mortality data, but no events were detected in many studies; only studies in which events were detected are included in the plot Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Effect of statins compared with placebo or no treatment on cardiovascular mortality in pre-dialysis, dialysis, and transplant Patients Only studies with at least one event are included in the plot Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Effect of statins compared with placebo or no treatment on cardiovascular events in pre-dialysis, dialysis, and transplant Patients Only studies with at least one event are included in the plot Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Effect of statins compared with placebo or no treatment on acute allograft rejection in renal transplant recipients Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Multivariate meta-regression analysis of potential sources of heterogeneity on effect of statins versus placebo on total cholesterol and low density lipoprotein cholesterol at end of treatment Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]

Withdrawal rates for statins compared with placebo in pre-dialysis, dialysis, and transplant patients Only studies with at least one withdrawal are included in the plot Strippoli GF, et al. BMJ 2008 Feb 25 [Epub ahead of print]